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Abstract
Background: Understanding the mechanism by which viruses enter their target cell is an essential part of
understanding their infectious cycle. Previous studies have focussed on the multiplicity of viral envelope proteins
that need to bind to their cognate receptor to initiate entry. Avian sarcoma and leukosis virus Envelope protein
(ASLV Env) mediates entry via a receptor, Tva, which can be attached to the cell surface either by a phospholipid
anchor (Tva800) or a transmembrane domain (Tva950). In these studies, we have now investigated the number of
target receptors necessary for entry of ASLV Env-pseudotyped virions.
Results: Using titration and modelling experiments we provide evidence that binding of more than one receptor,
probably two, is needed for entry of virions via Tva800. However, binding of just one Tva950 receptor is sufficient
for successful entry.
Conclusions: The different modes of attachment of Tva800 and Tva950 to the cell membrane have important
implications for the utilisation of these proteins as receptors for viral binding and/or uptake.
Background
Entry of a retrovirus into a cell represents one of the
most important steps in the viral life cycle. The virus
must first target cells expressing the appropriate recep-
tor, and once bound, overcome the energetic barrier
presented by the plasma membrane to enter the cell.
Within the family of Retroviridae, there are many varia-
tions in receptor type and usage. The nature of the
interaction between the retroviral envelope protein and
its cognate receptor and coreceptor (if used), are key to
understanding the process of viral entry. To date, most
in vitro and in silico studies of the quantitative aspects
of the interaction between trimeric viral envelope (Env)
protein and its cognate receptor have focussed on HIV-
1 and CD4 e.g. [1-5]. However, these are complicated by
the necessary interaction of the virus with both receptor
and coreceptor and the interdependence of CD4,
CXCR4 and CCR5 levels [6-9].
The alpharetrovirus ASLV-A can utilise one of two
receptors for entry, Tva800 or Tva950, which arise from
alternate splicing of a single gene [10,11]. Both comprise
identical 83-amino acid binding domains with an LDL-
A motif [11], but differ in their attachment to the mem-
brane. Tva800 has a C-terminal GPI anchor sequence,
but Tva950 is attached by a single transmembrane span-
ning domain. As a result, the receptors are localized to
different regions of the cell membrane; Tva800 is found
in lipid rafts, whereas Tva950 is excluded from these
areas [12]. The normal cellular functions of Tva800 and
Tva950 are not known.
Fusion mediated by ASLV Env and Tva800 or Tva950
requires a low pH step for entry via endosomes [13,14].
Virus binding triggers a conformational change in Env
that exposes the fusion peptide, which is then inserted
into the cellular membrane [13,15]. Exposure of the sen-
sitised Env to low pH in the endosomes will lead to
fusion of viral and cellular membranes [16]. Tva800 and
Tva950 possess the same N-terminal Env-binding and
fusion-mediating domain, but the kinetics of entry differ,
as Tva800 mediates the process more slowly [17,18].
For the present study, examination of the interaction
between ASLV-A Env and its two receptors was
initiated to investigate how the difference in attachment
might affect subsequent movement of ALSV-pseudo-
typed MLV into sub-cellular compartments, with corre-
sponding differences in susceptibility to the cellular
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restriction factors TRIM5a [19] and Fv1 [20]. However,
initial experiments revealed that even before the virus
enters the cell, the difference in membrane attachment
of the two receptors can affect virus uptake. The chance
isolation of a transducing vector expressing very low
levels of receptor presented the opportunity for the
investigation of the stoichiometric requirements for the
two forms of the receptor. Here, we present data that
are the counterpart of studies on the number of Env tri-
mers that must be bound for entry, namely the number
of receptors that must be bound. We found that binding
of more than one Tva800 is required for a virus to be
able to enter a cell, but that binding of a single Tva950
molecule is sufficient for entry. A possible explanation
for this difference is proposed.
Results
Generation of Tva800-positive cell populations
Initially intending to investigate the effect of different
uptake pathways on restriction by TRIM5 and Fv1, we
set out to prepare MDTF cells carrying receptors for a
number of orthoretroviral Env proteins, among them
Tva800. To construct one such cell line, the Tva800
gene was cloned into the vector pLgatewayIY [21].
Transduction of MDTF cells with one particular clone
of this construct at MOI 1 infectious unit (i.u.)/cell
yielded a polyclonal population of cells in which YFP-
positive cells can reasonably be expected to express
Tva800. When these cells were challenged with ASLV-A
Env-pseudotyped NB-MLV, the titration curve shown in
Figure 1A was obtained. This curve was not of the
expected shape; when more than 10 μl of tester virus
was added, the percentage of infected cells did not con-
tinue increasing as the volume of challenge virus
increased. The same curve was seen in two repeat
experiments. When the Tva800-YFP clone was
sequenced a single difference to the published sequence
for Tva800 (GenBank ID 403161) was identified. Instead
of the translational start codon of ATG, a codon of
AGG was found. It would be expected that this would
not result in any protein production when this vector
was transduced into cells. However, MDTF cells do not
harbour an endogenous receptor for ASLV-A Env-pseu-
dotyped virus, and proved to be completely non-permis-
sive when challenged without initial transduction of the
Tva800 vector (Figure 1A), implying some translational
activity of the mutant gene.
To test whether the T to G change was responsible
for the peculiar shape of the titration curves, the start
codon was restored by a point mutation of G to T, and
the titration curve was repeated, as shown in Figure 1B.
Cells were transduced with this second Tva800 vector
and then challenged with increasing amounts of ASLV-
A Env pseudotyped virus. The percentage of infected
cells rose rapidly and reached a plateau with nearly all
cells infected (Figure 1B). These data would suggest that
the mutant start codon was directly responsible for the
atypical titration curve seen with the first vector. The
two Tva800 vectors were denoted Tva800ATG and
Tva800AGG, according to their start codon sequence.
Protein analysis of Tva800 in cells transduced with HA-
Tva800ATG or HA-Tva800AGG
Given that Tva800 production has to take place to permit
entry of ASLV-A Env-pseudotyped challenge virus into
these cells, but that it is translated from a vector with an
altered start site, it seemed likely that only a limited level
of protein production occurred in these cells. This propo-
sition was tested by Western blot analysis. First, a 27-bp
sequence encoding an HA-tag was inserted into the
expression vectors just after the signal peptide between
residues 19 and 20 of Tva800. This 9 amino acid inser-
tion did not have any effect on viral infectivity of the two
Figure 1 Titration of ASLV-A Env pseudotyped NB-MLV on
MDTF cells transduced with Tva800AGG or Tva800ATG. Cells
were initially transduced at an MOI of approximately 1 i.u./cell with
a delivery virus expressing Tva800 and YFP and challenged 3 days
later with 5-600 μl ASLV-A pseudotyped NB-MLV expressing GFP
(tester virus). Cells were analyzed by two-colour FACS after a further
three days. Data are plotted as the percentage of delivery virus
transduced cells (YFP positive) infected by tester virus (GFP positive).
(A) Mock-transduced (open circles) and Tva800AGG (filled circles). (B)
Tva800ATG-transduced. Shown are the combined results of two
independent experiments for (A) and one experiment for (B).
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new vectors, HA-Tva800ATG or HA-Tva800AGG (data
not shown). Then, MDTF cells were transduced with
HA-Tva800ATG at MOIs from 0.006 to 6, or HA-
Tva800AGG at MOIs from 0.02 to 20i.u./cell. Proteins in
cell lysates were separated by polyacrylamide gel electro-
phoresis, and analyzed after transfer by probing with
either anti-HA, anti-YFP or, as loading control, anti-
GAPDH (Figure 2). No HA-tag or YFP expression was
detected with untransduced MDTF extract. As expected,
no difference was seen in YFP expression with the two
vectors, consistent with YFP production from the IRES
being unaffected by the Tva800 start codon. By contrast,
when probing for the HA-tag, bands were seen in the
cells transduced with the HA-Tva800ATG vector at
MOIs of 0.6 or above. This band had a somewhat lower
mobility than expected from its amino acid content, pre-
sumably as a result of N-linked glycosylation at 3 sites
[11]. Cells transduced with HA-Tva800AGG did not pro-
duce detectable levels of receptor protein, even when
transduced at MOI 20 i.u./cell, despite producing signifi-
cant levels of YFP protein at MOI 2 and 20 i.u./cell
These data show that the level of Tva800 production
Figure 2 Analysis of Tva800 expression in transduced cells. MDTF cells were seeded in 60 mm dishes and transduced at the MOI (i.u./cell)
shown with HA-Tva800ATG or HA-Tva800AGG. Cells were grown to confluence over 3 days, lysed with loading buffer, denatured and separated
on a gel and examined by Western blotting, probing with firstly anti-HA, and secondly anti-GFP on the same gel. The blot was stripped and
probed for GAPDH to check for comparable input lysate levels. Markers for molecular weight are shown on the left in kDa.
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from HA-Tva800AGG transduced cells is at most 30-fold
lower than that from cells transduced with HA-
Tva800ATG and likely substantially less.
Increasing Tva800AGG normalises challenge virus
titration curves
If the low levels of Tva800 at the surface of the trans-
fected cells are indeed responsible for the abnormal
titration curves of cells transduced with Tva800AGG,
transduction of cells at higher MOI should result in
increased numbers of proviruses per cell leading to
higher levels of Tva800 transcription and thus to higher
levels of protein expression, potentially converting the
curve shown in Figure 1A to that seen in Figure 1B. To
test this idea, MDTF cells were transduced with
Tva800AGG at MOI 1, 5, 10 and 20, then challenged
with between 2-600 μl of tester virus. As the MOI at
which cells were transduced with Tva800AGG
increased, the resulting titration curves show shallower
decreases in the number of cells infected with increasing
tester virus dose (Figure 3). Increasing the MOI to 20i.
u./cell resulted in a titration curve of the challenge virus
that was essentially indistinguishable from that produced
on challenge of cells transduced with Tva800ATG. This
result is consistent with the hypothesis that low Tva800
receptor levels are responsible for the abnormal shape
of the titration curves.
Competition between SUA-rIgG and ASLV-A Env
pseudotyped GFP vector virus
If the effective concentration of Tva800 on
Tva800AGG-transduced cells is limiting, then infection
of these cells should be particularly sensitive to competi-
tion with free receptor. To test the effect on viral titre
mediated by increased blocking of free receptor, a con-
stant volume of virions carrying GFP vector was titrated
onto cells in competition with increasing volumes of
SUA-rIgG. SUA-rIgG is a hybrid protein comprising the
SU of ASLV-A Env linked to rabbit immunoglobulin G
that can bind to receptors through the SU portion, and
so block binding of GFP vector virus to Tva800. This
experiment can directly indicate whether cells trans-
duced with Tva800AGG express significantly less recep-
tor than cells transduced with Tva800ATG, and the
fraction of the GFP virus preparation composed of
empty virions remains constant and can be ignored.
SUA-rIgG was able to compete with ASLV Env-pseu-
dotyped virions as shown in Figure 4. Doubling the
amount of SUA-rIgG in the challenge dose reduced the
percentage of cells infected by half in cells transduced
Figure 3 Tester virus titration in cells transduced with
Tva800AGG at different multiplicities. MDTF cells transduced
with Tva800AGG at MOI 1, 5, 10 or 20 i.u./cell were challenged with
5-600 μl ASLV-A Env pseudotyped NB-MLV and analyzed by two-
colour FACS as described in the legend to Figure 1. The combined
results of two independent experiments are shown. Error bars
represent standard deviation of the mean.
Figure 4 SUA-rIgG competition of ALSV-A Env mediated
infection. Cells transduced with Tva800 vectors were challenged
with 10 μl ASLV-A Env pseudotyped NB-MLV mixed with 0-500 μl of
SUA-rIgG-containing supernatant,. Infection was assessed by two-
colour FACS as described above. (A) Tva800AGG, MOI 0.14, 1.4 and
11. (B) Tva800ATG, MOI 0.16, 1.6, and 8. Representative results from
three (A) and four (B) experiments performed are shown.
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with Tva800AGG (Figure 4A), but no decrease was
observed in the proportion of virions entering the cells
transduced with Tva800ATG at MOI 1.6 or 8 (Figure
4B). There is a lag in decline of infectivity in cells trans-
duced at MOI 11 with Tva800AGG presumably because
these cells express sufficient receptor to sustain a small
increase in blocking agent. In cells transduced with the
lowest level of Tva800ATG, at MOI 0.16 (Figure 4B), a
decrease of just over half of the maximum (59% to 26%)
was seen. However, if this decrease is compared to cells
transduced with Tva800AGG at a similar MOI (0.14), a
decrease from a maximum of 7.8% cells GFP positive to
less than 1% is seen. The final four data points show
levels of GFP-positive cells that are below the limit of
detection, suggesting that the fold-decrease might be
much greater than 7.8. These data would support those
shown in Figure 2, and the hypothesis that cells trans-
duced with Tva800AGG produce significantly less
Tva800 than cells transduced with Tva800ATG.
Similar effects are not seen with Tva950
As discussed above, the ALSV-A receptor is found in
two forms, Tva800 and Tva950. They are identical in
the extracellular domain, including the viral envelope
binding motifs, but differ in their attachment to cells
[11]. Both are composed of identical 83-amino acid sec-
tions, after which Tva950 has a membrane-spanning
domain, and Tva800 has a C-terminal GPI anchor signal
sequence, and, after undergoing post-translational modi-
fication, will be attached to the lipid membrane via a
GPI anchor. To assess whether the unusual titration
curves obtained with low levels of Tva800 could be
related to its attachment to the cell membrane, a com-
parison of the effects of low Tva950 production on the
permissivity of cells to increasing doses of ASLV-A Env
virions was performed. Tva950 was cloned into pLGate-
wayIY, after which the start codon of the resulting vec-
tor was mutated to AGG. The two vectors were named
Tva950ATG and Tva950AGG respectively. They are
identical to the corresponding Tva800 plasmids other
than the 149 nucleotide insertion near the 3’ end of the
ORF that distinguish the two forms of the gene.
Figure 5 shows data from an experiment using these
vectors to introduce the Tva950 receptor. Tva950
appears to be utilized less efficiently than Tva800 as
judged by the shallower slope with the wild type form
(compare Figure 1B with Figure 5). Cells transduced
with Tva950AGG are less susceptible to infection than
Tva950ATG; this effect can be overcome by transduc-
tion with higher MOI (Figure 5). However, in contrast
to Tva800, there was no evidence for an inhibitory effect
when high concentrations of tester virus were applied to
cells presumed to carry low concentrations of receptor
(i.e. transduced with Tva950AGG).
Modelling the effects of limiting receptor on virus entry
We hypothesized that the limiting factor for viral entry
might be free receptor and that virus must bind more
than one receptor molecule to enter a cell. The low
levels of Tva800 at the surface of cells transduced with
low MOI of Tva800AGG would thus lead to reduced
amounts of free, unbound receptor that become limiting
for viral uptake with increasing doses of the tester virus.
Consequently, with increasing virus challenge, more vir-
ions (bound only to one receptor) fail to enter the cell,
either remaining at the cell surface or internalized but
not fused, and the number of cells infected decreases.
Application of a mathematical model gave an explana-
tion for these results in terms of physical parameters.
The use of differential equations and probabilistic meth-
ods to mathematically model viral systems is well estab-
lished [22-24], and here a range of standard
mathematical techniques were applied to simulate the
various stages of the experiment. Full details of the
model are given in additional file 1. Results from the
model, and for the experimental data, are shown in Fig-
ure 6 and Table 1. The results for Tva950 suggest that
this system is well characterised by a model in which a
single receptor is required for the tester virus to gain
entry to the cell, in which the efficiency of the delivery
vector is high, but the receptor efficiency is low. In the
case where the tester virus needs to bind a single recep-
tor to gain entry to the cell, increasing the MOI of the
tester virus means that there are more viruses available
to bind receptors, which increases the proportion of
cells that are successfully transduced with the tester
virus. This consistent increase is observed in the data
for Tva950 (compare Figure 6A with Figure 5).
By contrast, the data with Tva800 suggest that this sys-
tem is best characterised by a model in which more
Figure 5 Titration of ASLV-A Env pseudotyped NB-MLV on
MDTF cells transduced with Tva950AGG or Tva950ATG. Cells
transduced with the levels shown of Tva950ATG or Tva950AGG (i.u./
cell) were challenged with 5-500 μl ASLV-A Env pseudotyped NB-
MLV and analyzed by two-colour FACS as described in the legend
to Figure 1.
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than one receptor is needed for the tester virus to gain
entry to the cell (Figure 6B-D). Whereas, in the one
receptor model, increasing the tester virus MOI always
increases the likelihood of receptors being bound by
viruses, and hence increases EGFP expression, this is
not the case where more receptors are needed for viral
entry. In the latter case, a competitive process occurs, in
which viruses bound to receptors on the cell gradually
accumulate more receptors, up to the number required
for viral entry, while viruses in solution bind free recep-
tors on the cell. In this case, an initial increase in the
MOI of the tester virus increases the number of viruses
available to bind receptors, increasing the proportion of
cells expressing EGFP. However, when the MOI of the
Figure 6 Relationship between efficiency of ASLV-A Env mediated virus entry and the number of Tva800 or Tva950 receptors needed
for entry. The relative levels of receptor positive cells infected (% cells transduced, Y-axis) when titrating virus (μl, X-axis) onto cells previously
transduced with different amounts of a vector encoding Tva800 or Tva950. Graph (a) shows the model for Tva950 when 1 receptor is needed,
(b)-(d) assume binding of 1-3 Tva800 receptors, respectively. Data from the multiple-receptor model is not shown for Tva950. We note that the
one-receptor model is a special case of the multiple-receptor model (the latter will approach the former as gamma tends to infinity). As the fit
for the one-receptor model is very good, any results for larger numbers of receptors would be extremely close to those described here.
Table 1 Optimised parameters from the mathematical model describing the proportion of MDTF cells expressing EYFP
that also expressed EGFP
System Number of receptors








Number of receptors produced




Relative rate at which bound
viruses acquire more receptors g
Tva950 1 0.0258 1 1.579 0.198 n/a
Tva800 1 0.106 0.25 0.921 1 n/a
Tva800 1 0.176 1* 0.925 0.300 n/a
Tva800 2 0.120 1 0.979 0.992 9.837
Tva800 3 0.165 1 0.990 1 159.3
In each case the number of receptors needed for viral entry was fixed, while other parameters were optimised to maximise the fit to the experimental data. A
calculation for Tva800 with one receptor needed for viral entry was rerun, with the efficiency of the delivery vector fixed to match that obtained for Tva950. The
error D gives the RMSD difference between the model and the experimental data in each case. Efficiencies are expressed as probabilities, such that an efficiency
of 1 is equivalent to 100%.
*parameter fixed, not optimised
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tester virus becomes large, the rate of binding of free
receptors by virions in solution overtakes the rate at
which virions already bound to the cell acquire addi-
tional receptors. Virions binding fewer than the required
number of receptors for entry can occupy all of the
receptors before a single virus binds enough of them to
gain entry to the cell, so the proportion of cells expres-
sing EGFP decreases. This behaviour, characterised by
an initially increasing proportion of cells expressing
EGFP followed by a decline at high tester virus MOI, is
observed in the experimental data for Tva800.
Table 1 shows optimised parameters for each of the
models. For the Tva950 receptor, a model in which a
single receptor was required for viral entry gave a good
fit to the experimental data. We note that the model
systems for Tva800 where two or three receptors were
needed for a virus to gain entry into the cell both gave
optimal values for the efficiency of the delivery virus
equal to that found for Tva950. Of these models, that in
which two receptors were needed for viral entry gave a
better fit to the data (lowest model error in Table 1).
Discussion
There has been considerable recent interest in under-
standing the stoichiometric aspects of viral binding and
entry; however, previous studies have tended to concen-
trate on the stoichiometry of viral envelope binding in
relation to entry [1-4]. Theoretical models presented
here show how low surface receptor expression could
also affect viral binding and entry. Relating the models
shown in Figure 6 to the experimental data presented
here would suggest that binding of more than one
Tva800, probably two, by a virus is necessary in order
for the virus to enter the cell, but that binding of only
one Tva950 is sufficient. It must be emphasized that our
study should not be taken as suggesting a physiological
role for AGG mediated translation; rather, we have
taken advantage of this observation to study normal
receptor requirements for virus uptake.
Our study started with a chance observation related to
poor efficiency of Tva800 receptor transfer and presum-
ably stems from a random PCR error affecting the trans-
lational start site of this gene. We showed that Mus
dunni cells alone are non-permissive to infection
mediated by ASLV Env, but the introduction of the
Tva800 AGG vector renders them permissive to infec-
tion. It had previously been shown that expression of
low levels of either Tva800 or Tva950 protein is both
necessary and sufficient for infection by ASLV-A Env
pseudotyped virions [11]. Therefore, after the transduc-
tion of MDTF cells with the Tva800AGG vector, func-
tional Tva800 protein must be expressed at some level
on the cell surface. This requires in-frame initiation of
protein synthesis downstream of the transcription start
site, but upstream of the Tva800 signal sequence
required for protein sorting, which is predicted to lie in
the N-terminal 19 amino acids of Tva [11], without an
intervening translation stop site. To examine this issue,
we sequenced the whole Tva800 AGG vector. The
(DNA) sequence of the transcript encoding Tva800,
from transcriptional start to the translation stop at the
end of the ORF, is shown in Additional file 2. The
Tva800 ORF, including its AGG start site, is shown in
blue. All ATGs upstream of the Tva800 ORF are high-
lighted in red, and stop codons in-frame with the ORF
are underlined. Examination of this sequence reveals an
opal stop codon 60 nucleotides upstream of the Tva800
ORF with no intervening AUG. Alternatively, RNA spli-
cing might juxtapose an in frame ATG with the ORF.
Indeed in silico analysis [25] revealed that the T to G
alteration in the normal start codon yields a possible
splice acceptor site. However, the only upstream splice
donor predicted was the normal Mo-MLV splice donor
at position 223 (GenBank Accession Number
AFO33811) and there are no ATG triplets before this.
We therefore conclude that the Tva800 ORF is trans-
lated using a non-canonical start codon. Such start sites
are not unknown, but are more usually found in plant
genomes, bacteria, yeast, and viruses, and initiation is
much weaker than from AUG [26-31]. There is, how-
ever, an in frame CTG triplet, the most commonly used
alternative start codon in mammals [28,31], between -61
and the normal start site. The vectors Tva950AGG and
Tva800AGG are identical in their backbones, including
the promoter and intergenic regions, and only differ
near the 3’ end of the Tva ORF hence the potential start
site of Tva950AGG must be the same as Tva800AGG.
Irrespective of the exact start site, translation of the
Tva800AGG and Tva950AGG is likely to be inefficient.
Nevertheless, given the need for a leader peptide, it
seems likely that the structure of the expressed ectodo-
main seen by virus will be the same as with wild type
receptor.
Application of a mathematical model gave an under-
standing of the physical processes underlying the
observed behaviour of the cells. Optimising the para-
meters of the model to fit the experimental results sug-
gested a differing mode of viral entry to the cell via the
Tva800 and Tva950 receptors. The receptor efficiency
for Tva800 was high, at close to 100%, while the recep-
tor efficiency for Tva950 was low, at around 20%. It
must be considered how similar or different really are
the mechanisms of the two receptors, Tva800 and
Tva950. A comparison of the graphs in Figures 3
(Tva800) and 5 (Tva950) with the theoretical models
shown in Figure 6 would suggest that there is a signifi-
cant difference between the two. The two forms of the
receptor differ only in their attachment to the
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membrane and the localised milieu of the plasma mem-
brane (Tva800 resides in lipid rafts) [12]. Tva950 is
associated with faster rates of internalization, probably
due to a faster rate of endocytosis and lateral diffusion
of the receptor over the cell membrane [17,18]. Tva800
did not appear to increase the rate of endocytosis over
non-specific levels, possibly because as a GPI-anchored
receptor lacks the intracellular domain that can partici-
pate in signalling and recruitment of endocytic appara-
tus. Plasma membrane proteins attached via a GPI
anchor are only associated with the outer leaflet of the
plasma membrane and it is possible that the perturba-
tion to the cell membrane necessary for fusion of viral
and cellular membranes, and hence viral entry, is more
readily achieved when the receptor spans both leaflets,
as is the case for Tva950. It is also possible that, since
Tva800 is not anchored to both leaflets, it is more
prone to being extruded from the cell membrane due to
the force exerted on it subsequent to virus binding, in
comparison to Tva950.
One possibility not explicitly included in the model is
that Tva800 and Tva950 might exist in clusters so that
incoming viruses hit more than one receptor at once. If
Tva950 is found in clusters, the apparent result that
only one receptor is needed for entry into the cell could
arise from the simultaneous binding of multiple recep-
tors, as a virus interacts with a single cluster (the mathe-
matical model does not differentiate between a single
receptor, or a cluster of multiple receptors). For Tva800,
however, whether the virus initially binds to a cluster or
a receptor, there is a clear requirement for further bind-
ing to free clusters or free receptors that must take
place before entry, shown by the decrease in infection
when high titres of virus are used. Whether receptors
occur in isolation, as assumed by the model, or in clus-
ters, the same qualitative result, of the virus needing to
bind multiple Tva800 receptors/clusters as opposed to a
single Tva950 receptor/cluster stands, though the pre-
cise number of receptors required would be quantita-
tively different if clusters formed in significant numbers.
Overall, the data presented here show that low levels of
receptor expression can prevent high titres of virus from
being able to enter cells if the virus needs to bind more
than one receptor in order to do so. Studying these
effects is important for applications involving gene ther-
apy in clinical settings. Traditionally it has been assumed
that a high viral titre is necessary in order for entry of
proportions sufficient to achieve the desired effect
[32,33]. However, this assumption and strategy could be
counter-productive if viral envelopes and receptor com-
binations with entry requirements such as ASLV Env and
Tva800 are used, as excessive numbers of virions would
actually inhibit entry rather than increase titres.
Conclusions
We show that viral entry via Tva950 requires one recep-
tor, and via Tva800 requires more than one receptor,
probably two. The difference is due to the two modes of
attachment to the receptors to the cell membrane. The
simplicity of the ASLV Env, Tva800 and Tva950 system,
without additional factors or co-receptors, lends itself as
an advantageous model to facilitate further studies in
the area of viral entry.
Methods
Cells and viruses
Mus dunni tail fibroblast (MDTF) and 293T cells were
cultivated in Dulbecco modified Eagle medium supple-
mented with 10% fetal calf serum and antibiotics.
Viruses were generated by transient transfection of
293T cells with three plasmids providing vector, gag-pol,
and env by a conventional CaPO4 method as described
previously [34]. Briefly, 1 day before transfection, 293T
cells were seeded at 2 × 106 cells in 5 ml culture med-
ium on 6-cm-diameter dishes. For preparing the “deliv-
ery” vector viruses, 7 μg each of pVSV-G [34], pHIT60
(MLV gag-pol) [35], and delivery vector plasmids were
transfected simultaneously. For preparing ASLV-A-pseu-
dotyped NB-MLV “tester” viruses, which carry enhanced
green fluorescent protein (EGFP), 293T cells were trans-
fected with 7 μg each of pLNCG [21], pHIT60 and
pCB6-EnvA, [36]. Medium containing SUA-rIgG was
prepared by transfection of 293T 10 μg of the plasmid
pSUA-rIgG (a gift of John Young) [37] as for tester
viruses. At 18 h after transfection, cells were treated
with 10 mM sodium butyrate for 6 h to stimulate cyto-
megalovirus promoter-driven expression. At 48 h after
transfection, the virus-containing culture supernatant
was harvested, filtered through a 0.45 μm-pore-size fil-
ter, and stored immediately at -80°C. Titres of viral
stocks were established by FACS.
Generation of Tva containing plasmids
Plasmids expressing Tva800 and Tva950 [11] were gifts
from John Young. The products of amplification of
Tva800 and Tva950 (nucleotides 41-405 and 41-554 of
GenBank Accession Numbers L22752 and L22753
respectively) were cloned into pLgatewayIY [21] result-
ing in MoMLV LTR-promoter driven Tva and IRES-
YFP vectors using methods described in [34]. Plasmids
Tva800AGG and Tva950ATG were generated in this
fashion with the T to G change in Tva800AGG presum-
ably resulting from an error during PCR. Mutation of
Tva800AGG to Tva800ATG, and Tva950ATG to
Tva950AGG was done by PCR site-directed mutagenesis
using PfuUltra DNA polymerase (Stratagene) according
to the manufacturer’s protocol with the following
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oligonucleotides. Tva800AGG; forward, CCGCCCC
CTTCA CCATGGAGAGGATGATGCC and reverse,
GGCAGCAGCCGCGCCATGGTGAAGGGGGCGG.
Tva950 ATG; forward CCCCCTTCACCAGGGAGAG-
GATGC TG and reverse, CAGCAGCCGCGCCCT
GGTGA AGGGGG. The nine amino acid HA-tag was
inserted into plasmids between amino acids 23 and 24
of Tva800 and Tva950 by insertional PCR using the fol-
lowing oligonucleotides. Forward, TACCCTTAC-
GATGTTCCTGATTACGCTAACGGGTCCGGTAA
CGGTTCTTT GTCCCG and reverse CGCGTAAT-
CAGGAACATCGTAAGGGTAACCGGTCACGTTA
CCGGGCAGC. The final, mutated sequences were veri-
fied by sequencing.
Assay of Tva dependent entry
Assays for entry were carried out as described previously
for Fv1 restriction assays [34]. Briefly, 5 × 104 MDTF
cells per well were seeded on a 12-well plate. Sixteen
hours later, cells were challenged with delivery vector
virus to transduce the Tva800ATG, Tva800AGG,
Tva950ATG or Tva950AGG construct and EYFP.
Approximately 48 h later, cells were split 1:12, and after
a further 16 h, they were challenged with ASLV-A Env-
pseudotyped tester virus to transduce EGFP. Cells were
inoculated with aliquots of delivery virus at MOIs (a
ratio of the number of infectious units per target cell,
defined by measurement of virus on a permissive cell
line) of less than 1 to over 20 infectious units/cell, and
tester virus levels of between 1-600 μl, or < 1-99% green
cells in control cells, which were MDTF cells transduced
with pLgateway800IG which constitutively express the
Tva800 receptor. When cells were infected with tester
virus in competition with SUA-rIgG, the viral dose was
maintained at 10 μl with 0-500 μl SUA-rIgG-containing
medium, made up to 510 μl in PBS. Forty-eight hours
after the second transduction, cells were harvested, fixed
in phosphate-buffered saline (PBS)-3.5% formalin, and
examined for EGFP and EYFP expression by fluores-
cence-activated cell sorting analysis with a fluorescence-
activated cell sorter LSR apparatus (Becton Dickinson).
Titres of virus were assessed by calculating the percen-
tage of GFP-positive cells in the YFP-positive cell
populations.
Western blot
MDTF cells transduced at different MOI of the
Tva800ATG or Tva800AGG constructs were seeded in
60 mm plates and grown to confluence. The cells were
washed with PBS twice, and lysed in 500 μl 1xSDS load-
ing buffer (50 mM Tris-HCl, 100 mM DTT, 2% SDS,
0.1% Bromophenol Blue, 10% glycerol) at 95°C, and
removed from the plates using a cell scraper. The sam-
ples were boiled for 10 minutes, cleared by
centrifugation, and separated by polyacrylamide gel elec-
trophoresis. Proteins were then transferred onto a poly-
vinylidene difluoride membrane, and incubated
overnight in blocking buffer (PBS containing 5% milk
and 0.1% Tween 20) at 4°C overnight. The membrane
was incubated in blocking buffer containing polyclonal
anti-HA (Sigma) (1 in 5,000 dilution) or anti-a-tubulin
(Sigma) (1 in 10,000 dilution) antibody at room tem-
perature for 1 hour. After the membrane was washed, it
was incubated at room temperature for 1 hour in block-
ing buffer containing horseradish peroxidase-conjugated
anti-rabbit immunoglobulin G antibody (1 in 20,000
dilution) for HA detection or horseradish peroxidase-
conjugated protein A (1 in 10,000 dilution) for a-tubulin
detection. After the membrane was washed, the protein
bands were detected using the enhanced chemilumines-
cence (ECL) system (Amersham).
Mathematical modelling of viral entry
A statistical model was applied to calculate the theoretical
percentage of MDTF cells expressing EYFP that also
expressed EGFP. The values for the MOIs of the delivery
vector virus and the tester virus that were used in the
experiment were taken as inputs to the model, and five
parameters were used to describe the physical behaviour
of the system. Describing the interaction with the delivery
vector virus, the efficiency of the delivery vector, p, was
defined as the probability that an interaction of a cell with
a delivery vector virus would lead to the expression of
Tva, while the number of receptors produced by a cell per
delivery provirus was described by the parameter r.
Describing the interaction of the tester virus with recep-
tors on the cell, the number of receptors a virus needed to
bind to gain entry to the cell was described by the para-
meter k, while the receptor efficiency q was defined as the
probability that the binding of a virus to k receptors would
lead to the expression of EGFP. For systems in which tes-
ter viruses needed to bind more than one receptor to gain
entry into the cell, a final parameter, g, described the ratio
between the rate at which viruses in solution bound to
receptors on the cell, and the rate at which viruses already
bound to receptors on the cell surface acquired more
receptors. For selected values of k, the other parameters
were optimised through a computational process to give
the best fit to the experimental data. Full details of the
model are given in additional file 1.
Additional material
Additional file 1: Details of the mathematical model. A description of
the derivation of a statistical model to calculate the percentage of MDTF
cells expressing EYFP that also expressed EGFP.
Additional file 2: Partial sequence of the Tva800AGG vector from R-
U5 to the end of the Tva800 ORF. Sequence of a region of plasmid
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Tva800AGG. Stop codons in-frame with the Tva800 ORF have been
underlined, ATG codons are marked in red, and the Tva800 ORF is in
blue.
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